Medtronic PLC $MDT Stock Holdings Boosted by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management increased its Medtronic stake by 436.1% in Q4, adding 1,299,948 shares to own 1,598,005 shares worth about $153.5 million (≈0.12% of the company).
• EVP Harry Skip Kiil sold 52,524 shares on Feb. 19 at an average price of $97.71 for roughly $5.13 million, reducing his holding by 61.58%; corporate insiders now own about 0.26% of the stock.
• Medtronic declared a quarterly dividend of $0.71 (annualized $2.84, ~3.3% yield) payable April 17 with record date March 27, and reported a slight Q earnings beat while setting FY2026 guidance of $5.62–$5.66 EPS.

Robeco Institutional Asset Management B.V. lifted its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 436.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,598,005 shares of the medical technology company's stock after acquiring an additional 1,299,948 shares during the period. Robeco Institutional Asset Management B.V. owned 0.12% of Medtronic worth $153,504,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Baker Tilly Wealth Management LLC grew its position in shares of Medtronic by 3.3% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company's stock worth $309,000 after acquiring an additional 102 shares during the last quarter. Riverbend Wealth Management LLC grew its position in shares of Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company's stock worth $332,000 after acquiring an additional 107 shares during the last quarter. Maseco LLP grew its position in shares of Medtronic by 32.1% during the fourth quarter. Maseco LLP now owns 444 shares of the medical technology company's stock worth $43,000 after acquiring an additional 108 shares during the last quarter. Holistic Financial Partners grew its position in shares of Medtronic by 3.0% during the third quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company's stock worth $352,000 after acquiring an additional 109 shares during the last quarter. Finally, Wynn Capital LLC grew its position in shares of Medtronic by 2.4% during the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company's stock worth $442,000 after acquiring an additional 110 shares during the last quarter. Institutional investors own 82.06% of the company's stock.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.26% of the stock is owned by corporate insiders.

Medtronic Stock Performance

Shares of MDT opened at $87.17 on Friday. The firm has a 50-day moving average price of $93.08 and a 200 day moving average price of $95.97. The firm has a market capitalization of $111.91 billion, a PE ratio of 24.28, a P/E/G ratio of 2.26 and a beta of 0.75. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 52-week low of $79.93 and a 52-week high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic's dividend payout ratio is currently 79.11%.

Analysts Set New Price Targets

Several equities analysts have recently commented on MDT shares. CICC Research started coverage on shares of Medtronic in a research report on Friday, January 30th. They set an "outperform" rating for the company. Stifel Nicolaus lowered their price target on shares of Medtronic from $105.00 to $95.00 and set a "hold" rating for the company in a research report on Monday, April 6th. JPMorgan Chase & Co. lowered their price target on shares of Medtronic from $105.00 to $100.00 and set a "neutral" rating for the company in a research report on Wednesday, February 18th. Argus lowered their price target on shares of Medtronic from $125.00 to $115.00 and set a "buy" rating for the company in a research report on Monday, April 6th. Finally, Barclays upped their price target on shares of Medtronic from $118.00 to $120.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 1st. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $109.00.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.